The peak sales forecast for AstraZeneca Efzimfotase Alfa is expected to reach 5 billion US dollars, and executives believe this bone disease drug is expected to be approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.